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Abstract 
Polymeric microparticles are micro carriers for the sustained drug delivery of drugs in the lungs, used as 
alternatives to the use of established excipients. This study aims to develop and characterize inhalable 
ciprofloxacin (CPx)-loaded poly(vinyl alcohol) (PVA) microparticles by a single-step spray-drying 
procedure. 
Disciplines 
Engineering | Science and Technology Studies 
Publication Details 
Silva, D. M., Paleco, R., Traini, D. & Sencadas, V. (2018). Development of ciprofloxacin-loaded poly(vinyl 
alcohol) dry powder formulations for lung delivery. International Journal of Pharmaceutics, 547 (1-2), 
114-121. 















































































































































































































































0.5 15	 ⁄ 	 0.999 . The drug content and entrapment efficiency were 
calculated with Equation 1 and 2: 
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d(0.1) / µm d(0.5) / µm d(0.9) / µm Span
PVA 0.36 ± 0.01 3.30 ± 0.03 5.85 ± 0.10 1.67±0.02
PVA‐CPx 0.35 ± 0.02 3.20 ± 0.13 6.77 ± 0.38 2.00±0.03
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  MMAD (µm)  GSD  FPF < 5 µm (%) 
SD‐CPx  5.33±0.39  2.13±0.30  30.43±1.38 
PVA‐CPx  5.06±0.10  1.98±0.39  39.78±0.98 
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